MANNKIND CORP

MNKD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Revenue $109.4M $90.2M $112.0M $82.1M $76.5M $78.4M $76.8M $70.1M
Cost of Revenue $14.4M $7.5M $13.9M $4.5M $4.6M $3.8M $4.8M $3.2M
Gross Profit $95.0M $82.7M $98.0M $77.6M $71.9M $74.6M $72.0M $66.9M
Gross Margin 86.8% 91.7% 87.6% 94.5% 94.0% 95.2% 93.7% 95.4%
Operating Expenses
Research & Development
SG&A Expense $58.3M $54.1M $58.4M $29.1M $31.6M $25.0M $24.0M $23.9M
Operating Income $-350.0K $-1.7M $-7.7M $18.9M $5.3M $22.3M $26.5M $12.8M
Operating Margin -0.3% -1.8% -6.9% 23.0% 6.9% 28.5% 34.5% 18.2%
Interest Expense
Pretax Income $-19.1M $-16.4M $-20.9M $7.8M $940.0K $13.6M $8.4M $12.9M
Income Tax Expense $-106.0K $253.0K $-5.0M $-204.0K $272.0K $459.0K $1.0M $1.3M
Net Income $-19.0M $-16.6M $-15.9M $8.0M $668.0K $13.2M $7.4M $11.6M
Net Margin -17.4% -18.4% -14.2% 9.7% 0.9% 16.8% 9.7% 16.5%
EPS (Basic) $-0.06 $-0.05 $-0.05 $0.03 $0.00 $0.04 $0.03 $0.04
EPS (Diluted) $-0.06 $-0.05 $-0.05 $0.03 $0.00 $0.04 $0.03 $0.04
Shares Outstanding (Basic) 309.2M 308.3M 305.6M 306.8M 305.0M 303.5M 274.4M 275.0M
Shares Outstanding (Diluted) 309.2M 308.3M 314.1M 311.6M 311.5M 320.9M 283.8M 284.7M
Dividends Per Share
← Newer Page 1 of 7 Older →